26 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00781 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-549 | Lung cancer | IC50 : 9.7 µMo/L |
| dbacp00782 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | A-375 | Skin cancer | IC50 : 8.7 µMo/L |
| dbacp00783 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | MCF-7 | Breast cancer | IC50 : 6.2 µMo/L |
| dbacp00784 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | SW-1116 | Colorectal cancer | IC50 : 4.3 µMo/L |
| dbacp00785 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | RD | Rhabdomyosarcoma cancer | IC50 : 6.4 µMo/L |
| dbacp00786 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | H-1299 | Lung cancer | IC50 : 4.1 µMo/L |
| dbacp00787 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | B-16 | Skin cancer | IC50 : 4.4 µMo/L |
| dbacp00788 | A12L/A20L | KWKSFLKTFKSLKKTVLHTLLKAISS | PeptideV13K | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2 µMo/L |
| dbacp05405 | Peptide K14D | KWKSFLKTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.52 ± 0.05 µMol/L |
| dbacp05406 | Peptide K14D/K22D | KWKSFLKTFKSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.40 ± 0.09 µMol/L |
| dbacp05407 | Peptide K1D/K3D/K7D /K10D/K14D/K22D | kWkSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 18.07 ± 0.48 µMol/L |
| dbacp05408 | Peptide K22D | KWKSFLKTFKSLKKTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.39 ± 0.02 µMol/L |
| dbacp05409 | Peptide K3D/K7D /K10D/K14D/K22D | KWkSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 20.41 ± 0.64 µMol/L |
| dbacp05410 | Peptide K7D | KWKSFLkTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.29 ± 0.03 µMol/L |
| dbacp05411 | Peptide K7D /K10D/K14D/K22D | KWKSFLkTFkSLKkTVLHTLLkAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.79 ± 0.23 µMol/L |
| dbacp05412 | Peptide K7D /K14D | KWKSFLkTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.06 ± 0.01 µMol/L |
| dbacp05413 | Peptide K7D /K14D/K22D | KWKSFLkTFKSLKkTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 4.45 ± 0.19 µMol/L |
| dbacp05414 | Peptide L12D | KWKSFLKTFKSlKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.63 ± 0.07 µMol/L |
| dbacp05415 | Peptide L12D/L20D | KWKSFLKTFKSlKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.14 ± 0.06 µMol/L |
| dbacp05416 | Peptide L20D | KWKSFLKTFKSLKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.33 ± 0.06 µMol/L |
| dbacp05417 | Peptide L6D | KWKSFlKTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 2.23 ± 0.10 µMol/L |
| dbacp05418 | Peptide L6D/L12D | KWKSFlKTFKSlKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 3.01 ± 0.08 µMol/L |
| dbacp05419 | Peptide L6D/L12D/L17D/L20D | KWKSFlKTFKSlKKTVlHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 9.69 ± 0.38 µMol/L |
| dbacp05420 | Peptide L6D/L12D/L17D/L20D/L21D | KWKSFlKTFKSlKKTVlHTllKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 12.88 ± 0.15 µMol/L |
| dbacp05421 | Peptide L6D/L12D/L20D | KWKSFlKTFKSlKKTVLHTlLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 7.80 ± 0.26 µMol/L |
| dbacp05427 | Peptide P | KWKSFLKTFKSLKKTVLHTLLKAISS | A12L/A20L | Membrane disruption mechanism | MTT/MTS assay | HeLa | Cervical cancer | IC50 : 1.71 ± 0.07 µMol/L |